The development of JAK inhibitors has provided new avenues for targeted cancer therapy. These inhibitors are designed to block the abnormal JAK signaling that promotes cancer cell growth and survival. Ruxolitinib is a JAK1/2 inhibitor that has shown efficacy in treating myeloproliferative disorders. Other JAK inhibitors, such as Tofacitinib and Baricitinib, are also being explored for their potential in treating various cancers.